Aggribloc

Aggribloc Uses, Dosage, Side Effects, Food Interaction and all others data.

Aggribloc prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation.

Aggribloc prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation. When administered intravenously, tirofiban inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner. When given according to the recommended regimen, >90% inhibition is attained by the end of the 30-minute infusion. Aggribloc has been recently shown in patients with unstable angina to reduce ischemic events at 48 hours following infusion when compared to standard heparin therapy.

Table Of contents

• Aggribloc
• Uses
• Dosage
• Side Effect
• Precautions
• Interactions
• Uses during Pregnancy
• Uses during Breastfeeding
• Accute Overdose
• Food Interaction
• Half Life
• Volume of Distribution
• Clearance
• Interaction With other Medicine
• Contradiction
• Storage

Trade Name	Aggribloc
Availability	Prescription only
Generic	Tirofiban
Tirofiban Other Names	Tirofiban, Tirofibán, Tirofibanum
Related Drugs	clopidogrel, Plavix, Brilinta, enoxaparin, ticagrelor, Lovenox
Weight	5mg,
Type	Infusion
Formula	C22H36N2O5S
Weight	Average: 440.597 Monoisotopic: 440.234492962
Protein binding	65%
Groups	Approved
Therapeutic Class
Manufacturer	Abbott Healthcare Pvt Ltd
Available Country	India,
Last Updated:	September 19, 2023 at 7:00 am

Uses

Aggribloc is a platelet aggregation inhibitor used to prevent thrombotic events in non-ST elevated acute coronary syndrome.

For treatment, in combination with heparin, of acute coronary syndrome, including patients who are to be managed medically and those undergoing PTCA or atherectomy.

Aggribloc is also used to associated treatment for these conditions: Cardiovascular Events

How Aggribloc works

Aggribloc is a reversible antagonist of fibrinogen binding to the GP IIb/IIIa receptor, the major platelet surface receptor involved in platelet aggregation. Platelet aggregation inhibition is reversible following cessation of the infusion of tirofiban.

Food Interaction

No interactions found.

Aggribloc Hypertension interaction

[Major] The use of gp11b<111a platelet inhibitors is contraindicated in patients with active internal bleeding, recent significant gastrointestinal or genitourinary bleeding (within 6 weeks), recent trauma or major surgery (within 6 weeks), history of bleeding diathesis, recent stroke (within 4 weeks), history of hemorrhage stroke or residual neurologic deficit, intracranial defect (aneurysm, arteriovenous malformation, neoplasm), uncontrolled hypertension (SBP > 180; DBP > 110), or thrombocytopenia (

Aggribloc Drug Interaction

Major: enoxaparin, heparin, clopidogrelModerate: aspirinUnknown: epinephrine, albumin human, spironolactone, RHO Immunoglobulin , insulin glulisine, hydralazine, phytonadione, amoxicillin / clavulanate, sulfamethoxazole / trimethoprim, glucose, isosorbide mononitrate, furosemide, atorvastatin, multivitamin, sodium chloride, acetaminophen

Aggribloc Disease Interaction

Major: bleeding risks, renal dysfunction

Volume of Distribution

• 22 to 42 L

Half Life

2 hours

Clearance

• 213 - 314 mL/min [Healthy subjects]
• 152 - 267 mL/min [patients with coronary artery disease]

Elimination Route

It is cleared from the plasma largely by renal excretion, with about 65% of an administered dose appearing in urine and about 25% in feces, both largely as unchanged tirofiban.

Innovators Monograph

You find simplified version here Aggribloc